IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Ipsen expects Increlex supply interruption due to issues at Lonza Hopkinton site

6:20 AM MDT | April 29, 2013 | Deepti Ramesh

Pharmaceutical company Ipsen (Paris) says that it expects a supply interruption for its product Increlex, a treatment for growth failure in children, as a result of the manufacturing issues at Lonza’s Hopkinton, MA, site that supplies the active ingredient for Increlex. The US in 2011 to Lonza’s pharmaceutical and active pharmaceutical ingredient manufacturing facility at Hopkinton for deviating from cGMP. Lonza is working with the FDA to address these issues and Ipsen is addressing management of the shortage to reduce its impact on the patients and...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa